Become Affiliate

PepFlow

Download

The GLP-1 Standard

Semaglutide

A long-acting GLP-1 receptor agonist available as injection and tablets, used in modern obesity, diabetes, cardiovascular-risk, and kidney-outcome research and care.

Weight loss
TierS
EvidenceStrong
SafetyWell-Studied
FDA statusApproved
Last reviewed October 25, 2026 53 citations How to read these labels

What is Semaglutide?

Semaglutide is a modified GLP-1 receptor agonist designed to last far longer than native GLP-1. The molecule activates the GLP-1 receptor, slows gastric emptying early in treatment, increases glucose-dependent insulin secretion, suppresses glucagon when glucose is elevated, and reduces appetite through central satiety pathways.[1][2]

For chronic weight management, the strongest evidence comes from large STEP trials of once-weekly subcutaneous semaglutide 2.4 mg, including weight-loss, maintenance, and two-year follow-up data.[6][8][9]

Semaglutide also has large outcome trials in type 2 diabetes, cardiovascular-risk reduction, chronic kidney disease, and oral semaglutide cardiovascular outcomes. Those results make it very different from research-market peptides with only mechanism or animal data.[11][10][12][13] For more context, read the semaglutide reconstitution terminology guide.

What Semaglutide is investigated for

Semaglutide evidence is grouped by practical use case and injectable, oral, intranasal, sublingual, buccal, ophthalmic, transdermal, and inhaled route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

Body-weight reduction and maintenance

Injectable, Oral

95%Strong

Semaglutide is strongly supported for weight management when used as the labeled drug product in the right population and clinical setting.[1][6]

Human evidence

STEP trials show large and sustained weight reductions with subcutaneous semaglutide 2.4 mg, including maintenance data and two-year follow-up.[6][8][9]

Animal / mechanistic evidence

Mechanistic support comes from GLP-1 receptor effects on appetite, satiety, gastric emptying, and energy intake, but the human trial evidence is the main reason confidence is high.[1]

Type 2 diabetes glycemic control

Injectable, Oral

92%Strong

The diabetes use case is strong, but dose, route, and concomitant glucose-lowering therapy matter for hypoglycemia and tolerability.[2][3]

Human evidence

Semaglutide injection and tablets have labeled diabetes indications, and STEP 2 shows weight and glycemic data in adults with type 2 diabetes and overweight or obesity.[2][3][7]

Animal / mechanistic evidence

The incretin mechanism is glucose-dependent, increasing insulin and reducing glucagon when glucose is elevated.[2]

Cardiovascular-risk reduction in selected populations

Injectable, Oral

88%Strong

Cardiovascular benefit should be interpreted by trial population and label, not as a blanket claim for every semaglutide user.[10][13]

Human evidence

SELECT, SUSTAIN-6, and SOUL support cardiovascular benefit in defined high-risk populations and product contexts.[10][11][13]

Animal / mechanistic evidence

Mechanistic explanations likely include weight, glycemic, blood-pressure, lipid, inflammatory, and direct tissue effects, but human trials carry the claim.[10]

Kidney protection in type 2 diabetes with CKD

Injectable

82%Strong

Confidence is high for the studied population, but it should not be generalized to kidney wellness claims outside that population.[12]

Human evidence

FLOW reported kidney benefit in patients with type 2 diabetes and chronic kidney disease.[12]

Animal / mechanistic evidence

The route-relevant mechanism is likely tied to metabolic, hemodynamic, and cardiometabolic effects rather than direct kidney-targeted peptide replacement.[12]

Neurodegenerative disease

Oral

45%Preliminary

Large Alzheimer's trials did not confirm clinical benefit, so semaglutide remains an investigated GLP-1 therapy rather than an established neurodegenerative-disease treatment.[52][51]

Human evidence

The EVOKE and EVOKE+ phase 3 trials tested oral semaglutide in early symptomatic Alzheimer's disease, but sponsor topline results reported no statistically significant reduction in disease progression versus placebo.[51][52]

Animal / mechanistic evidence

GLP-1 receptor biology remains under study in neurodegenerative disease, including Parkinson's disease, but this does not establish semaglutide as a neuroprotective treatment.[53]

Evidence snapshot

95%

Human evidence

Strong

Large STEP, SUSTAIN, SELECT, FLOW, and SOUL datasets support weight, glycemic, cardiovascular, kidney, and oral semaglutide outcomes in the populations studied.[6][11][10][12][13]

82%

Animal / preclinical

Strong

Nonclinical and pharmacology support explains GLP-1 receptor activity, but human trials and approved labeling are the main reason confidence is high.[1][2]

90%

Mechanism support

Strong

GLP-1 receptor activation links the observed outcomes to appetite regulation, gastric-emptying effects during initiation, glucose-dependent insulin secretion, and glucagon suppression when glucose is elevated.[1][2][3]

Forms & administration

Semaglutide is supplied in approved injection pens and oral tablets with product-specific instructions. Nasal, sublingual, buccal, eye-drop, microneedle and inhaled formulations remain experimental, with evidence mainly from animals or laboratory delivery work. Their exposure, amounts and preparation cannot be equated with approved products.[1][2][3][42][43][44][45][46][47][48]

InjectableOralNasal spraySublingualBuccalOphthalmicTransdermalInhaled

Dosing & protocols

These ranges are general reference points, not personal dosing instructions.

Typical Range

Injectable semaglutide starts at 0.25 mg weekly. Maintenance doses are 0.5-2.4 mg, or 7.2 mg for the high-dose product. Oral products use 1.5-25 mg daily.[1][2][3]

Frequency

Injectable products are taken once weekly. Oral tablets are taken once daily.[1][2][3]

Timing Considerations

Use injections on the same day each week. Take tablets in the morning on an empty stomach and wait 30 minutes before eating or drinking.[1][3]

Cycle Length

Treatment is ongoing. Standard dose increases take 3-4 months; the 7.2 mg dose requires at least 4 additional weeks.[1][8][9]

What to expect

First weeks

Appetite is usually the first change people notice: smaller portions feel more manageable and fullness can arrive sooner.[1][6]

3-6 months

Scale and waist changes usually become more visible, and appetite control can feel steadier as the routine settles.[6][8]

1 year and beyond

Many responders maintain a lower weight with continued treatment, and cardiometabolic markers may remain improved while the medication effect is present.[8][9][10]

After stopping

Appetite can return toward baseline and weight regain is common after semaglutide is stopped; blood pressure, glucose, and lipid improvements may also soften.[8][9][21]

Safety profile

Semaglutide has a well-characterized prescription-drug safety profile. The main practical issues are GI intolerance, dehydration risk, gallbladder and pancreatitis warnings, diabetes-medication interactions, retinopathy caution in diabetes, pregnancy planning, and the boxed thyroid C-cell tumor warning.[1][2][3]

Common side effects

Cautions

  • Thyroid C-cell tumor warning[1]
  • Pancreatitis and gallbladder disease[1]
  • Insulin or sulfonylureas[2][3]
  • Pregnancy planning[2]
  • Compounded or unapproved GLP-1 products[4]

Who Semaglutide is not for

Route-specific avoid and medical-review notes:

  • MTC or MEN2 history

    Semaglutide products are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN2.[1][2]

  • Pregnancy planning

    Labels instruct discontinuation before planned pregnancy because of semaglutide exposure and long washout considerations.[2]

Drug & supplement interactions

Documented interactions are separated from theoretical or route-specific cautions.

Documented interactions

  • Insulin or sulfonylureas

    Hypoglycemia risk can increase when semaglutide is combined with insulin secretagogues or insulin, so glucose-lowering therapy may need adjustment.[2][3]

  • Levothyroxine or monitored oral drugs

    Oral semaglutide delays gastric emptying and can change oral-drug exposure; the label specifically reports higher levothyroxine exposure and calls for closer monitoring of narrow-therapeutic-index or clinically monitored oral medicines.[3]

Pairing notes

Works well with

Nutrition and activity interventionInjectable, Oral

Nutrition and activity give semaglutide's appetite and weight-maintenance effects a structure to work inside: calorie targets, movement, and adherence routines support the medication effect rather than replacing it.[1][6]

Cagrilintide as an amylin partnerInjectable

Cagrilintide activates amylin pathways that increase satiety, while semaglutide activates GLP-1 pathways that reduce appetite and slow gastric emptying. Together they provide complementary appetite-control signals.[49][50]

Not recommended with

Tirzepatide: overlapping GLP-1 effectsInjectable, Oral

Semaglutide and tirzepatide both activate GLP-1 pathways. Using them during overlapping courses duplicates effects on appetite, gastric emptying, and glucose control and requires clinician direction.[1]

Retatrutide: overlapping GLP-1 effectsInjectable, Oral

Semaglutide and retatrutide both activate GLP-1 pathways. Overlapping them combines appetite, gastric-emptying, and glucose effects without an established combination regimen.[1]

How it works

Semaglutide is a long-acting GLP-1 receptor agonist. The practical effect is appetite and calorie-intake reduction, plus glucose-dependent insulin release and lower glucagon when glucose is elevated, without making hypoglycemia irrelevant when insulin or sulfonylureas are used.[1][2][6]

It also delays gastric emptying, which supports fullness but helps explain nausea, reflux-type symptoms, dehydration risk after vomiting or diarrhea, and oral-medicine timing concerns.[1][2][3]

Route and formulation matter: injectable and oral semaglutide have different exposure rules, and approved-product evidence does not make compounded, salt-form, or research-market products equivalent. Product and route drive the evidence.[1][3][4]

Research gaps & open questions

What the current literature has not yet settled about Semaglutide:

01

Direct comparisons between approved tablets and injections need to show which effects, side effects, and dose conversions are formulation-specific; the products should not be substituted one-for-one.[1][3]

02

Long-term studies still need better answers on maintaining weight loss, stopping treatment, preserving muscle, supporting nutrition, and keeping treatment accessible.[8][9]

Common questions

Is semaglutide a peptide?

Yes. It is a modified GLP-1 peptide analog, but it should be treated as a prescription drug product rather than a generic research peptide.[1]

Are oral and injectable semaglutide interchangeable?

No. They are different product routes with different dose forms and administration rules, even though the active ingredient is semaglutide.[1][3]

Does weight loss stay after stopping?

STEP 4 and related follow-up data show that continued treatment supports maintenance better than withdrawal; stopping can be followed by weight regain.[8][9]

Myths & misconceptions

Myth

Any semaglutide product is basically the same as Wegovy or Ozempic.

Reality

FDA-approved products have reviewed formulation, labeling, dose delivery, and quality controls. FDA has separately warned about unapproved GLP-1 products used for weight loss.[4][1]

Myth

Semaglutide is only a weight-loss drug.

Reality

Weight management is a major use case, but semaglutide also has diabetes, cardiovascular, oral-formulation, and kidney-outcome evidence in defined populations.[2][10][12]

History & discovery

Semaglutide moved GLP-1 therapy from diabetes glucose control into obesity and broader cardiometabolic outcomes. Its history matters because the same incretin biology supported injectable, oral, and obesity-dose programs rather than one narrow obesity discovery.[2][3][6][11]

SUSTAIN-6 established cardiovascular-outcome context in type 2 diabetes, and STEP 1 made once-weekly semaglutide 2.4 mg a modern obesity-drug reference point.[11][6]

SELECT, FLOW, SOUL, MASH research, and FDA GLP-1 safety materials widened the evidence story while keeping approved formulations separate from unapproved GLP-1 products and later liver-disease questions.[10][12][13][20][4]

Published research53 citations

Show citationsHide citations

PepFlow library coverage

Keep It Organized

Stay on track with your weight-management goals.

Use PepFlow to record your Semaglutide protocol, set reminders for your own schedule, and review your history.

Download on the App StoreGet it on Google Play
PepFlow calendar on Thursday, April 9, listing BPC-157 at 10:00 and GHK-CU at 18:00